Table 2.
Unadjusted Values for Blood Product Utilization and Early Post-operative Outcomes in Patients Receiving Aprotinin or Lysine Analogues
| Aprotinin(N=325) | Lysine Analogues*(N=456) | p-value | |
|---|---|---|---|
| Blood Product Utilization | |||
| Intra-operative/Early-post Operative (<24 hours) | |||
| Packed Red Blood Cells (units) | 1.37 ± 1.79 | 1.14 ± 1.88 | 0.01 |
| Fresh Frozen Plasma (units) | 0.68 ± 1.80 | 0.63 ± 1.78 | 0.65 |
| Cryoprecipitate (units) | 0.13 ± 0.98 | 0.18 ± 1.02 | 0.09 |
| Platelets (units) | 1.77 ± 4.58 | 1.54 ± 4.65 | 0.98 |
| Late Post-operative Period (>24 hours) | |||
| Packed Red Blood Cells (units) | 2.21 ± 5.42 | 1.64 ± 3.22 | 0.99 |
| Fresh Frozen Plasma (units) | 1.22 ± 3.25 | 0.61 ± 2.22 | 0.002 |
| Cryoprecipitate (units) | 0.13 ± 0.46 | 0.06 ± 0.25 | 0.04 |
| Platelets (units) | 0.65 ± 2.74 | 0.39 ± 1.29 | 0.18 |
| Factor VIIa % | 7.7 | 9.9 | 0.52 |
| Post-operative Outcome | |||
| MACCE | |||
| Operative Death (Y) % | 5.5 | 3.3 | 0.12 |
| Perioperative MI (Y) % | 0.0 | 0.2 | 1.00 |
| Reoperation for Bleeding (Y) % | 4.9 | 1.8 | 0.01 |
| Neurological Event Permanent (Y) % | 2.2 | 1.8 | 0.69 |
| Neurological Event Transient (Y) % | 3.4 | 1.3 | 0.05 |
| Intra-aortic Balloon Pump (Y)% | 1.9 | 2.9 | 0.37 |
| Prolonged Ventilatory/Respiratory Failure(Y) % | 22.5 | 20.2 | 0.44 |
| Renal | |||
| Renal Failure (Y) % | 9.2 | 9.0 | 0.91 |
| Renal Dialysis Required (Y) % | 4.9 | 2.4 | 0.06 |
*
-Lysine Analogues: tranexamic acid or aminocaproic acid. Values presented as mean+/− standard deviation or percent. P-values computed from Wilcoxon rank sum tests, or chi-Square test (Fisher’s exact test for vell counts less than 5). MACCE- Major adverse cardiovascular or cerebrovascular events.